Fiche centre
First Hospital of Shanxi Medical University
Taiyuan — China
Essais liés5clinical trials
VilleTaiyuanlocalisation
PaysChinalocalisation
SourcelocaleCSV/MySQL
Informations
centreSynchronisé depuis ClinicalTrials.gov — NCT06101940
Essais cliniques associés
5| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| Skeletal muscle biopsy (residual specimen) | Myopathies | À vérifier | NCT06101940 | Chinese Multicenter Clinical Outcome Cohort Study of Myotonic Dystrophy Type 1 (C-DMCOS-DM1) | ENROLLING_BY_INVITATION |
| Telitacicept | Myasthénie | Phase 3 | NCT06456580 | A Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis (UPSTREAM MG) | RECRUITING |
| Efgartigimod IV | Myasthénie | Phase 3 | NCT06298552 | ADAPT SERON — A Phase 3 Study to Evaluate the Efficacy and Safety of Efgartigimod IV in Patients With Acetylcholine Receptor Binding Antibody Seronegative Generalized Myasthenia Gravis | ACTIVE_NOT_RECRUITING |
| doublepres — The Diagnosis and Treatment of Resistant Hypertension, the Prevalence and the Prognosis | Hypertension | À vérifier | NCT01703780 | doublepres — The Diagnosis and Treatment of Resistant Hypertension, the Prevalence and the Prognosis | UNKNOWN |
| RC18 160mg | Myasthénie | Phase 2 | NCT04302103 | A Study of TACI（Transmembrane Activator and Calcium-modulator and Cyclophilin Ligand (CAML) Interactor）-Antibody Fusion Protein Injection (RC18) in Subjects With Systemic Myasthenia Gravis | COMPLETED |